Literature DB >> 35706127

Developmental Pathways Are Epigenetically Reprogrammed during Lung Cancer Brain Metastasis.

Jennifer A Karlow1,2, Siddhartha Devarakonda3, Xiaoyun Xing1,2, Hyo Sik Jang1,2,4, Ramaswamy Govindan3, Mark Watson4, Ting Wang1,2,5.   

Abstract

Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed and deadliest cancers worldwide, with roughly half of all patients initially presenting with both primary and metastatic disease. While the major events in the metastatic cascade have been identified, a mechanistic understanding of how NSCLC routinely and successfully colonizes the brain is largely unknown. Recent studies have begun demonstrating the role of epigenetic misregulation during tumorigenesis and metastasis, including widespread changes in DNA methylation and histone modifications. To better understand the role of altered DNA methylation in NSCLC metastasis to the brain, we measured DNA methylation during disease progression for 12 patients, globally profiling the methylation status of normal lung, primary lung tumor, and brain metastasis samples. The variation in methylation was similar during metastatic spread and primary tumorigenesis but less coordinated across genomic features during metastasis. The greatest recurrent changes during metastatic progression were methylation gains in DNA methylation valleys (DMV) harboring the constitutive heterochromatin mark H3K9me3 as well as bivalent marks H3K27me3 and H3K4me1. In a lymph node-derived cancer cell line, EZH2 binding within DMVs was lost, accompanied by an increase in DNA methylation, exemplifying epigenetic switching. The vast majority of the differentially methylated region-associated DMVs harbored developmental genes, suggesting that altered epigenetic regulation of developmentally important genes may confer a selective advantage during metastatic progression. The characterization of epigenetic changes during NSCLC brain metastasis identified recurrent methylation patterns that may be prognostic biomarkers and contributors to disease progression. SIGNIFICANCE: Altered DNA methylation in lung cancer brain metastases corresponds with loss of EZH2 occupancy at developmental genes, which could promote stem-like phenotypes permissive of dissemination and survival in different microenvironments. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 35706127      PMCID: PMC9357144          DOI: 10.1158/0008-5472.CAN-21-4160

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  47 in total

1.  Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome.

Authors:  J Roman-Gomez; A Jimenez-Velasco; X Agirre; J A Castillejo; G Navarro; L Garate; E San Jose-Eneriz; L Cordeu; M Barrios; F Prosper; A Heiniger; A Torres
Journal:  Leukemia       Date:  2006-05-11       Impact factor: 11.528

2.  Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions.

Authors:  Gabriel E Zentner; Paul J Tesar; Peter C Scacheri
Journal:  Genome Res       Date:  2011-06-01       Impact factor: 9.043

3.  GREAT improves functional interpretation of cis-regulatory regions.

Authors:  Cory Y McLean; Dave Bristor; Michael Hiller; Shoa L Clarke; Bruce T Schaar; Craig B Lowe; Aaron M Wenger; Gill Bejerano
Journal:  Nat Biotechnol       Date:  2010-05-02       Impact factor: 54.908

4.  Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development.

Authors:  Gennady Margolin; Hanna M Petrykowska; Nader Jameel; Daphne W Bell; Alice C Young; Laura Elnitski
Journal:  J Mol Diagn       Date:  2016-02-05       Impact factor: 5.568

5.  Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines.

Authors:  Francisco Sánchez-Vega; Valer Gotea; Hanna M Petrykowska; Gennady Margolin; Thomas C Krivak; Julie A DeLoia; Daphne W Bell; Laura Elnitski
Journal:  Epigenetics       Date:  2013-10-22       Impact factor: 4.528

6.  The 5-methylcytosine content of DNA from human tumors.

Authors:  M A Gama-Sosa; V A Slagel; R W Trewyn; R Oxenhandler; K C Kuo; C W Gehrke; M Ehrlich
Journal:  Nucleic Acids Res       Date:  1983-10-11       Impact factor: 16.971

Review 7.  Metastasis: from dissemination to organ-specific colonization.

Authors:  Don X Nguyen; Paula D Bos; Joan Massagué
Journal:  Nat Rev Cancer       Date:  2009-04       Impact factor: 60.716

8.  Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods.

Authors:  Michael Stevens; Jeffrey B Cheng; Daofeng Li; Mingchao Xie; Chibo Hong; Cécile L Maire; Keith L Ligon; Martin Hirst; Marco A Marra; Joseph F Costello; Ting Wang
Journal:  Genome Res       Date:  2013-06-26       Impact factor: 9.043

Review 9.  Origins of metastatic traits.

Authors:  Sakari Vanharanta; Joan Massagué
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

10.  Integrative analysis of 111 reference human epigenomes.

Authors:  Anshul Kundaje; Wouter Meuleman; Jason Ernst; Misha Bilenky; Angela Yen; Alireza Heravi-Moussavi; Pouya Kheradpour; Zhizhuo Zhang; Jianrong Wang; Michael J Ziller; Viren Amin; John W Whitaker; Matthew D Schultz; Lucas D Ward; Abhishek Sarkar; Gerald Quon; Richard S Sandstrom; Matthew L Eaton; Yi-Chieh Wu; Andreas R Pfenning; Xinchen Wang; Melina Claussnitzer; Yaping Liu; Cristian Coarfa; R Alan Harris; Noam Shoresh; Charles B Epstein; Elizabeta Gjoneska; Danny Leung; Wei Xie; R David Hawkins; Ryan Lister; Chibo Hong; Philippe Gascard; Andrew J Mungall; Richard Moore; Eric Chuah; Angela Tam; Theresa K Canfield; R Scott Hansen; Rajinder Kaul; Peter J Sabo; Mukul S Bansal; Annaick Carles; Jesse R Dixon; Kai-How Farh; Soheil Feizi; Rosa Karlic; Ah-Ram Kim; Ashwinikumar Kulkarni; Daofeng Li; Rebecca Lowdon; GiNell Elliott; Tim R Mercer; Shane J Neph; Vitor Onuchic; Paz Polak; Nisha Rajagopal; Pradipta Ray; Richard C Sallari; Kyle T Siebenthall; Nicholas A Sinnott-Armstrong; Michael Stevens; Robert E Thurman; Jie Wu; Bo Zhang; Xin Zhou; Arthur E Beaudet; Laurie A Boyer; Philip L De Jager; Peggy J Farnham; Susan J Fisher; David Haussler; Steven J M Jones; Wei Li; Marco A Marra; Michael T McManus; Shamil Sunyaev; James A Thomson; Thea D Tlsty; Li-Huei Tsai; Wei Wang; Robert A Waterland; Michael Q Zhang; Lisa H Chadwick; Bradley E Bernstein; Joseph F Costello; Joseph R Ecker; Martin Hirst; Alexander Meissner; Aleksandar Milosavljevic; Bing Ren; John A Stamatoyannopoulos; Ting Wang; Manolis Kellis
Journal:  Nature       Date:  2015-02-19       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.